Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lifileucel by Iovance Biotherapeutics for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Lifileucel by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Lifileucel by Iovance Biotherapeutics for Endometrial Cancer: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Lifileucel by Iovance Biotherapeutics for Primary CNS Lymphoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase I for Primary CNS Lymphoma. According to GlobalData,...
Lifileucel by Iovance Biotherapeutics for Rhabdomyosarcoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...
Lifileucel by Iovance Biotherapeutics for Ewing Sarcoma: Likelihood of Approval
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Iovance Biotherapeutics's Lifileucel?
Lifileucel is a cell therapy commercialized by Iovance Biotherapeutics, with a leading Phase II program in Cervical Cancer. According to...
Risk adjusted net present value: What is the current valuation of Iovance Biotherapeutics's Lifileucel?
Lifileucel is a cell therapy commercialized by Iovance Biotherapeutics, with a leading Phase II program in Giant Cell Tumor Of...